Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ishtu Hageman
Observed names:
H Ishtu,
Hageman, I.L.,
Hageman, Ishtu L.,
I Hageman,
I Hageman MD,
Ishtu L Hageman,
Ishtu L. Hageman
show all 7
Institutions:
Amsterdam UMC Location University of Amsterdam,
Amsterdam University Medical Centers,
Amsterdam Gastroenterology Endocrinology Metabolism,
University of Amsterdam
Observed institutions:
Amsterdam UMC Location University of Amsterdam,
Amsterdam University Medical Centers,
Amsterdam Gastroenterology Endocrinology Metabolism,
University of Amsterdam
ORCID:
0000-0002-3180-156X
Observed ORCID:
0000-0002-3180-156X
OpenAlex ID:
A5042839139
Burden of disease and increasing prevalence of inflammatory bowel disease in a population-based cohort in the Netherlands
2016
·
E. Joline de Groof
, Noortje G.M. Rossen
, et al.
·
European Journal of Gastroenterology & Hepatology
·
81
Systematic Review and Meta-analysis of Peripheral Blood DNA Methylation Studies in Inflammatory Bowel Disease
2022
·
Vincent Joustra
, Ishtu L Hageman
, et al.
·
Journal of Crohn s and Colitis
·
38
PDF
Development and validation of peripheral blood DNA methylation signatures to predict response to biological therapy in adults with Crohn's disease (EPIC-CD): an epigenome-wide association study
2025
·
Vincent W Joustra
, Andrew Y F Li Yim
, et al.
·
The Lancet. Gastroenterology & hepatology
·
29
Modulation of macrophage inflammatory function through selective inhibition of the epigenetic reader protein SP140
2022
·
Mohammed Ghiboub
, Jan Koster
, et al.
·
BMC Biology
·
28
PDF
Peripheral Blood DNA Methylation Signatures and Response to Tofacitinib in Moderate-to-severe Ulcerative Colitis
2023
·
Vincent Joustra
, Andrew Y F Li Yim
, et al.
·
Journal of Crohn s and Colitis
·
22
PDF
Long-term Temporal Stability of Peripheral Blood DNA Methylation Profiles in Patients With Inflammatory Bowel Disease
2022
·
Vincent Joustra
, Andrew Y.F. Li Yim
, et al.
·
Cellular and Molecular Gastroenterology and Hepatology
·
19
PDF
Carboxylesterase-1 Assisted Targeting of HDAC Inhibitors to Mononuclear Myeloid Cells in Inflammatory Bowel Disease
2021
·
Ahmed M I Elfiky
, Mohammed Ghiboub
, et al.
·
Journal of Crohn s and Colitis
·
18
PDF
Novel DNA methylome biomarkers associated with adalimumab response in rheumatoid arthritis patients
2023
·
Ishtu Hageman
, Femke Mol
, et al.
·
Frontiers in Immunology
·
13
Epigenetic Signatures Discriminate Patients With Primary Sclerosing Cholangitis and Ulcerative Colitis From Patients With Ulcerative Colitis
2022
·
Manon de Krijger
, Ishtu L. Hageman
, et al.
·
Frontiers in Immunology
·
11
Peripheral Blood DNA Methylation Profiles Do Not Predict Endoscopic Post-Operative Recurrence in Crohn’s Disease Patients
2022
·
Vincent W. Joustra
, Andrew Y. F. Li Yim
, et al.
·
International Journal of Molecular Sciences
·
9
PDF
A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn’s Disease
2022
·
Ahmed M. I. Elfiky
, Ishtu L. Hageman
, et al.
·
Cells
·
6
PDF
An exploratory single-cell analysis of peripheral blood mononuclear cells from vedolizumab-treated Crohn’s disease patients identifies response-associated differences among the plasmacytoid dendritic cells and classical monocytes
2025
·
Andrew Yung Fong Li Yim
, Ishtu Hageman
, et al.
·
Frontiers in Immunology
·
5
PDF
OP03 Highly stable epigenome-wide peripheral blood DNA methylation signatures accurately predict endoscopic response to adalimumab, vedolizumab and ustekinumab in Crohn’s disease patients: The EPIC-CD study
2023
·
V Joustra
, A Li Yim
, et al.
·
Journal of Crohn s and Colitis
·
4
PDF
OP29 Peripheral blood DNA methylation biomarkers accurately predict clinical- and endoscopic response to vedolizumab in a real-life cohort of Crohn’s Disease patients
2022
·
V Joustra
, I Hageman
, et al.
·
Journal of Crohn s and Colitis
·
3
PDF
Su1313 Epidemiology and Characteristics of Inflammatory Bowel Disease in a Large Population-Based Cohort in the Netherlands
2015
·
Elisabeth J. de Groof
, Noortje Rossen
, et al.
·
Gastroenterology
·
3
P823 DNA methylation profiles accurately predict vedolizumab response and remain stable during induction and maintenance treatment in Crohn’s disease
2020
·
V Joustra
, I Hageman
, et al.
·
Journal of Crohn s and Colitis
·
2
PDF
P198 An inflammatory serum metabolomic signature predicts response to vedolizumab treatment in people with Crohn’s Disease
2022
·
D Radford-Smith
, A Yates
, et al.
·
Journal of Crohn s and Colitis
·
1
PDF
Colonic biopsy-associated microbial signatures are predictive of response to anti-TNFα biological therapy in Crohn’s disease
2026
·
Konstantina Zafeiropoulou
, Ishtu L. Hageman
, et al.
·
Frontiers in Cellular and Infection Microbiology
PDF
P0543 Colonic biopsy-associated microbial signatures predict response to anti-TNFα biological therapy in Crohn’s disease
2026
·
K Zafeiropoulou
, I Hageman
, et al.
·
Journal of Crohn s and Colitis
PDF
Su1975: DECREASED CD8A AND CD8B EXPRESSING BLOOD T CELL POPULATIONS MAY PREDICT ADALIMUMAB AND INFLIXIMAB RESPONSE FAILURE IN CROHN’S DISEASE PATIENTS
2025
·
Femke Mol
, Andrew Y. Li Yim
, et al.
·
Gastroenterology
Tu1757 MUCOSA-ASSOCIATED MICROBIOME SIGNATURE PREDICTS THERAPY RESPONSE TO ANTI-TNFA IN CROHN'S DISEASE.
2024
·
Konstantina Zafeiropoulou
, Ishtu Hageman
, et al.
·
Gastroenterology
Tu1767 HIGHER PREDICTIVE POWER OF EPIGENETIC SIGNATURES FOR RESPONSE TO VEDOLIZUMAB AND USTEKINUMAB IN ANTI-TNF NAÏVE PATIENTS WITH ACTIVE CROHN'S DISEASE
2024
·
Sarah van Zon
, Vincent Joustra
, et al.
·
Gastroenterology
P592 Higher predictive power of epigenetic signatures for response to vedolizumab and ustekinumab in anti-TNF naïve patients with active Crohn’s disease
2024
·
S Van Zon
, V Joustra
, et al.
·
Journal of Crohn s and Colitis
PDF
P181 Combination of EPIC-CD epigenetic signatures accurately identifies non-response to multiple biologics in patients with active Crohn’s disease
2024
·
V Joustra
, A Li Yim
, et al.
·
Journal of Crohn s and Colitis
PDF
O61 Highly stable epigenome-wide peripheral blood DNA methylation signatures accurately predict response to adalimumab, vedolizumab and ustekinumab in Crohn’s disease patients
2023
·
Vincent Joustra
, Andrew Li Yim
, et al.
·
Gut
Show more works
View as search
Works count:
42
Citation count:
292
H-index:
9
I10-index:
9
Year
Topic
Type